BioCentury
ARTICLE | Company News

Daiichi Sankyo, Dainippon Sumitomo deal

June 2, 2014 7:00 AM UTC

Dainippon granted Daiichi exclusive rights in Brazil and Venezuela to commercialize antipsychotic Latuda lurasidone ( SM-13496). Daiichi is responsible for submitting regulatory applications in the territories. Dainippon declined to disclose when it expects Daiichi to submit the applications, but did say it expects Daiichi to launch the product in 2016. Daiichi also received an option to license commercialization rights to the antipsychotic agent in Argentina and Colombia. Dainippon will receive an upfront payment and is eligible for regulatory and sales milestones. Dainippon declined to disclose details, and Daiichi could not be reached. ...